Ganglioside epitopes for treating guillain-barre syndrome
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 7, 2012
Grant Date -
Jun 2, 2011
app pub date -
May 27, 2010
filing date -
Aug 18, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully